Skip to main content

Table 3 Baseline characteristics of the entire cohort and propensity score matched cohort

From: Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy

Characteristics

Before matching (N = 1139)

After matching (N = 348)

Non-antiviral group (N = 216)

Antiviral group (N = 923)

SD

Non-antiviral group (N = 174)

Antiviral group (N = 174)

SD

Age (yr)

51.5 ± 11.5

51.1 ± 10.1

0.336

52.1 ± 11.2

51.5 ± 10.8

0.626

Male sex

144 (66.7%)

703 (76.2%)

8.283

113 (64.9%)

108 (62.1%)

0.310

Diabetes

40 (18.5%)

217 (23.5%)

2.496

29 (16.7%)

25 (14.4%)

0.351

Alcohol consumption

6 (2.8%)

28 (3.0%)

0.040

3 (1.7%)

2 (1.1%)

0.203

Ascites

176 (81.5%)

722 (78.2%)

1.114

138 (79.3%)

140 (80.5%)

0.072

WBC (×109/L)

4.5 (3.0, 7.0)

4.1 (2.8, 6.2)

0.418

4.6 (3.1,7.2)

4.8 (3.1, 7.3)

−0.309

PLT (×109/L)

69.0 (44.4, 119.0)

63.0 (45.4, 88.4)

15.353

68.5 (44.4, 119.2)

69.0 (49.4, 96.3)

5.467

HGB (g/l)

80.0 ± 23.7

88.7 ± 25.5

−8.659

81.0 ± 23.5

82.2 ± 22.9

−1.163

ALT (U/L)

22.5 (16.8, 32.6)

22.9 (17.1, 33.0)

−3.452

22.8 (16.6, 32.9)

21.4 (16.5, 32.8)

0.464

AST (U/L)

28.4 (22.3, 41.2)

29.3 (21.9, 41.2)

−1.642

28.4 (21.8, 40.1)

28.0 (21.8, 39.4)

−0.006

TBIL (μmol/l)

18.1 (11.9, 24.9)

18.1 (12.6, 25.2)

−2.486

17.3 (11.4, 24.6)

16.1 (11.2, 23.7)

−1.240

GGT (U/L)

22.6 (12.7, 44.0)

20.7 (13.8, 35.6)

3.292

23.4 (13.1, 37.3)

21.6 (13.3, 33.5)

1.455

ALB (g/l)

31.5 ± 5.3

33.3 ± 5.8

−1.800

31.9 ± 5.2

31.9 ± 5.8

−0.039

Cr (μmol/l)

59.2 (48.5, 72.3)

64.2 (54.6, 75.4)

−2.655

58.5 (48.6, 72.1)

59.9 (48.8, 70.6)

4.031

PT (s)

15.3 (14.1, 16.7)

14.9 (13.7, 16.2)

0.332

15.2 (14.1, 16.5)

15.3 (14.0, 16.6)

−0.100

AFP (ng/ml)

2.5 (1.6, 4.6)

3.0 (1.8, 5.8)

−2.205

2.5 (1.6, 4.6)

3.3 (2.0, 5.9)

−2.293

HBeAg (positive)

18 (10.3%)

231 (30.0%)

28.471

18 (10.3%)

24 (13.8%)

0.975

HBV-DNA (positive)

28 (23.7%)

186 (31.0%)

2.492

25 (24%)

35 (29.2)

0.747

MELD score

5.6 (2.7, 8.4)

6.2 (3.9, 8.8)

−0.910

5.4 (2.6, 8.3)

5.0 (1.8, 8.2)

0.430

CTP class (A/B/C)

39/130/47

219/525/179

3.312

35/106/33

29/102/43

1.955

  1. Data are presented as mean ± standard deviation, or number (percentage). In the entire cohort, 718 patients detected HBV-DNA, 224 patients detected HBV-DNA after matching
  2. SD standardised difference, WBC white blood cell, PLT Platelet, HGB hemoglobin, ALT alanine aminotransferase, TBIL total bilirubin, GGT gamma-glutamyl transpeptidase, ALB albumin, Cr creatinine, PT prothrombin time, AFP alpha fetoprotein, HBeAg hepatitis B virus e antigen, HBV-DNA hepatitis b virus deoxyribonucleic acid, CTP class Child-Turcotte-Pugh class, MELD model for end-stage liver disease